more_reports

Gritstone bio Inc.

GRTS:NASDAQ

Gritstone bio, a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to potentially drive the patient's immune system to specifically attack and destroy tumors.

streetwise book logo Streetwise Company Fact Sheet

2024/11/2 12:38:29

(GRTS:NASDAQ)